> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Reducing Zika Transmission by Blood/Blood Components
- URL: https://www.fdaweb.com/guidance-on-reducing-zika-transmission-by-blood-blood-components/
- Published: 2016-08-31T12:00:00.000Z
- Updated: 2026-09-14T21:28:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136670

*Federal Register* Notice: FDA is making available a guidance, *Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components; Guidance for Industry.* The document is notifying blood establishments that collect whole blood and blood components, that FDA has determined Zika virus to be a relevant transfusion-transmitted infection and provides the agency’s assessment and recommendations to reduce the risk of transmission. It applies to the collection of whole blood and blood components and not the collection of source plasma. The guidance supersedes the February document entitled, *Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus: Guidance for Industry* and the March document entitled, *Questions and Answers Regarding ‘Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus: Guidance for Industry* no later than 12 weeks after the date of the issuance of this guidance. To download the revised guidance, click [here.](http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213?ref=fdaweb.com) To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-08-31/pdf/2016-20914.pdf?ref=fdaweb.com)